Market Report Coverage and Key Metrics Market Dynamics Drivers Shift to Oral Formulations The shift to oral formulations is a main driver of the GLP-1 market because it directly removes patient barriers, simplifies daily routines, needle anxiety, and eliminates complex cold chain logistics
This multi-layered approach to Notch pathway inhibition represents a particularly effective strategy given the pathways crucial role in cell fate decisions
[DOI] [PubMed] [Google Scholar] 103.Zhao Y., Ye X., Xiong Z., Ihsan A., Ares I., Martnez M., Lopez-Torres B., Martnez-Larraaga M.R., Anadn A., Wang X., et al
This creates a cycle where elevated histamine leads to more oestrogen, which leads to more histamine
A recent study shows people with obesity taking GLP-1 drugs are 20% less likely to suffer a cardiovascular event, and studies are under way for their use to treat the liver disease non-alcoholic steatohepatitis, as well as the neurodegenerative conditions Parkinsons and Alzheimers
Results vary
